Dextran-Based CD206 Targeting Compounds for Macrophage Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective targeting and treatment of diseases mediated by CD206-high expressing cells, such as macrophages, which are involved in inflammatory, autoimmune, and infectious conditions, due to limited specificity and duration of action of existing therapeutic agents.
Innovation Solution
Development of dextran-based compounds with CD206 targeting moieties and therapeutic agents linked via hydrazone linkers, allowing specific binding and prolonged action on CD206-expressing cells, enabling targeted diagnosis and treatment of diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing therapeutic agents are used, then treatment can be provided, but the duration of action is limited and specificity is insufficient
Solution Approach 1:
The compound is divided into distinct functional segments: a dextran core structure, CD206 targeting moieties (mannose units), and therapeutic agent components. This segmentation allows each part to perform its specific function independently - the dextran provides structural framework, the mannose units provide specific CD206 binding, and the therapeutic agent provides treatment, thereby achieving both high specificity and prolonged duration of action
Solution Approach 2:
The invention creates a composite molecular structure combining dextran polysaccharide with mannose targeting moieties and therapeutic agents. This composite approach integrates the advantages of each component: dextran's stability and solubility, mannose's specific binding to CD206 receptors on macrophages, and the therapeutic agent's treatment capability, resulting in a compound that simultaneously achieves high specificity and extended duration of action
2Reliability
If therapeutic agents are administered, then treatment effect is achieved, but the action duration is short
Solution Approach 1:
The compound is designed to pre-target CD206-expressing cells through specific mannose-CD206 binding before the therapeutic agent exerts its full effect. This preliminary binding action anchors the therapeutic agent at the target site, ensuring both effective treatment and prolonged local action as the agent is released and acts on the bound complex
Solution Approach 2:
The stable dextran-mannose-therapeutic agent complex maintains continuous therapeutic action at the target site. The strong CD206 binding prevents rapid clearance, while the controlled release of the therapeutic agent from the complex ensures continuous treatment effect over an extended period, thereby achieving both high efficacy and prolonged duration of action
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dextran-based compounds effectively target and accumulate in CD206-expressing cells, providing prolonged therapeutic action and diagnostic imaging capabilities, enhancing treatment efficacy for diseases like tuberculosis and autoimmune disorders.
Implementation Method 1
Tilmanocept has a small molecular size (7 nanometers) and carries multiple units of mannose. This mannose component has a high affinity for CD206 which is found in high concentrations on the surface of macrophages, dendritic cells and other cells. By tightly binding to these mannose receptors, Tilmanocept accumulates in lymphatic tissue within minutes
Implementation Method 2
Development of dextran-based compounds with CD206 targeting moieties and therapeutic agents linked via hydrazone linkers, allowing specific binding and prolonged action on CD206-expressing cells
Data Source
AI summary
Provided are compounds and compositions for targeting macrophages and other CD206 high expressing cells.